Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
Running, not enrolling · Phase 1
Conditions studied: Multiple Myeloma in Relapse, Multiple Myeloma, Multiple Myeloma of Bone, Multiple Myeloma With Failed Remission
In brief
Researchers want to learn if MK-4002 (also known as HPN217) can treat relapsed or refractory multiple myeloma (RRMM). The goals of this study are to learn about the safety of different doses of MK-4002 and how well people tolerate them. Researchers also want to learn what happens to different doses of MK-4002 in a person's body over time.
Key facts
- Study ID
- NCT04184050
- Run by
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- People needed
- 100
- Starts
- 2020-04-13
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2025-12-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Banner MD Anderson Cancer Center — Gilbert, Arizona, United States
- Mayo Clinic Arizona — Phoenix, Arizona, United States
- UC San Diego Moores Cancer Center — La Jolla, California, United States
- The University of Kansas Cancer Center — Fairway, Kansas, United States
- Roswell Park Comprehensive Cancer Center — Buffalo, New York, United States
- University of Rochester James P Wilmot Cancer Institute — Rochester, New York, United States
- OHSU — Portland, Oregon, United States
- University of Washington - Seattle Cancer Center Alliance — Seattle, Washington, United States
- Centre Hospitalier Universitaire De Nantes — Nantes, France
- Centre Hospitalier Universitaire de Poitiers — Poitiers, France
- Josep Carreras Leukaemia Research Institute — Barcelona, Spain
- Hospital Universitario Fundacion Jimenez Diaz (UAM-FJD) — Madrid, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.